Abbreviations: AER, albumin excretion rate; ASA, acetylsalicylic acid; BP, blood pressure; GFR, glomerular filtration rate; TER alb , transcapillary escape rate of albumin; alb , fractional clearance of albumin.
I
n patients with type 1 diabetes, microalbuminuria has been shown to be a predictor of both micro-and macrovascular complications (1) (2) (3) (4) . Since low-dose acetylsalicylic acid (ASA) has been shown to offer substantial primary (5, 6) and secondary protection against macrovascular morbidity and mortality in diabetic patients at high risk for cardiovascular events (7) , ASA should now be considered a primary prevention strategy in high-risk patients with type 1 or type 2 diabetes if no contraindications exist (8) .
Elevated renal synthesis of vasodilating prostaglandins is present in type 1 diabetic patients with microalbuminuria (9) , and treatment with high-dose cyclooxygenase inhibitors reduces urinary albumin excretion rate (AER) in type 1 diabetic patients with microalbuminuria (150 mg indometacin daily) (9) or diabetic nephropathy (990 mg ASA ϩ 225 mg dipyridamole daily or 150 mg indometacin) (10, 11) . This effect occurs shortly after initiation of treatment and may lead to an incorrect classification of the level of albuminuria (normo-, micro-, and macroalbuminuria) and jeopardize the monitoring effect of antiproteinuric treatment (e.g., ACE inhibition). Whether similar difficulties exist using low-dose ASA remains to be elucidated.
The primary aim of the present study was to investigate the effect of short-term low-dose ASA on urinary AER as well as the effect on glomerular filtration rate (GFR) and endothelial function in type 1 diabetic patients with microalbuminuria.
RESEARCH DESIGN AND METHODS

Patients
Seventeen consecutive type 1 diabetic patients with persistent microalbuminuria (urinary AER between 30 and 300 mg/24 h in at least two of three sterile urine samples) were enrolled. All patients had been insulin dependent from the time of diagnosis and all were receiving at least two daily injections of insulin. Patients were excluded if they had systolic blood pressure (BP) Ͼ200 mmHg, were users of cyclooxygenase inhibitors, had acute gastritis or peptic ulcer disease, or if they were pregnant. During the investigation, patients received their usual antihypertensive treatment (n = 15; ACE inhibitors [n = 14] and/or non-ACE inhibitors [n = 11]). The study protocol was in accordance with the Helsinki Declaration. All subjects included in the study were Caucasians, and all gave informed consent to participate. The study was approved by the local ethics committee.
Hansen and Associates
Crossover design All patients entered a randomized doubleblind crossover trial. With concealed randomization, patients were allocated to take one tablet of ASA (150 mg) or one matching placebo tablet per day (in the morning). After 4 weeks of treatment, there was at least a 2-week washout period before patients crossed over to the opposite treatment for another 4 weeks.
Methods
Patients were investigated at the end of each treatment period of the double-blind crossover phase. All of the investigations were carried out with the patients in the supine position between 8:00 A.M. and 1:00 P.M. The investigations were started in the morning after an overnight fast. Patients had breakfast and their morning insulin after the start of the GFR investigation. They drank 150-200 ml tap water per hour during the study period.
Transcapillary escape rate of albumin At 8:30 A.M. after 30 min of rest, an intravenous injection of 40 kBq 125 I-labeled human serum albumin was given (code MIAK; Institute of Atomic Energy, Kjeller, Norway), and eight venous blood samples were drawn 10, 15, 20, 30, 40, 50, 55, and 60 min after the injection. Transcapillary escape rate of albumin (TER alb ) was determined as the rate constant of the monoexponential decrease in plasma radioactivity over the first 60 min after injection of tracer albumin, as calculated by the least square method and as described in detail by Parving et al. (12) . Thus, TER alb is defined as the fraction of intravascular mass of albumin leaving the vascular bed per hour (percent per hour).
GFR GFR was measured after a single intravenous injection of 3.7 MBq 51 Cr-EDTA immediately after termination of the TER alb examination, by determining the radioactivity in venous blood samples taken 180, 200, 220, and 240 min after the injection (13) . Extra renal loss was corrected for by subtracting 3.7 ml/min 1 (14) . The small underestimation (10%) of 51 Cr-EDTA renal clearance versus renal clearance of insulin was corrected for by multiplying the EDTA clearance by 1.10 (14) . The results were standardized for 1.73 m 2 body surface area. The mean dayto-day coefficient of variation in the GFR is 4% in our laboratory. Urinary albumin excretion and fractional clearance of albumin On the basis of the three consecutive 24-h urine collections completed immediately before each visit, urinary albumin excretion was measured by an enzyme-linked immunosorbent assay (coefficient of variation was 2.1%) (15 
Statistical analysis
Results are expressed as means ± SD or 95% CI as appropriate. Urinary excretion of albumin and alb are logarithmically transformed before statistical analysis because of their positively skewed distribution and are given as geometric mean (95% CI). Changes in variables between visits are expressed as means (95% CI). All comparisons of normally or log-normally distributed parameters were done with a paired Student' s t test. Data were tested for a period effect and a treatment-period interaction with a two-sample t test (16). Before the present study, we calculated the SD (log 10 scale: 0.1771) of the mean difference in urinary AER in three consecutive 24-h urine samples collected twice within 3 months in 36 type 1 diabetic patients with diabetic nephropathy. On the basis of these data, a sample-size calculation revealed a necessary minimum of 16 patients to detect a 25% difference in change in urinary AER (␣ = 0.05 and ␤ = 0.8). All calculations were made using Statistical Package for Social Science program for Windows (SPSS, Chicago). A P value of Ͻ0.05 was considered significant (two-tailed). 
Low-dose ASA and microalbuminuria
RESULTS
Randomized double-blind crossover phase All randomized patients completed the study. Table 1 shows the clinical characteristics of the patients. Table 2 shows data for urinary AER, alb , and GFR after each of the two treatment periods. Table 3 shows the data of TER alb , systolic and diastolic BPs, and HbA 1c after each of the two treatment periods.
No change in medication except shift from ASA and placebo tablets and vice versa was recorded in any patient during the investigation. On average, the washout period was 19.4 days (95% CI 17.0-21.7). Nine patients were smokers.
During the first treatment period, eight patients received ASA and nine received placebo. Neither a period effect (ASA/placebo vs. placebo/ASA; average differences [log 10 scale] -0.018 ± 0.35 vs. -0.092 ± 0.38, P = 0.68) nor a treatment-period interaction (ASA/placebo vs. placebo/ASA; average levels [log 10 scale] 1.69 ± 0.24 vs. 1.87 ± 0.39, P = 0.28) upon urinary AER was found.
Compliance
Using simple tablet counting, adherence was high, with Ͼ99% of tablets taken during period one and Ͼ97% taken during period two (NS). Blood ASA was not measured.
Side effects
No significant differences in side effects were observed between treatment with 150 mg ASA and placebo. Dyspepsia was equally reported during treatment with low-dose ASA and placebo (n [%]: 3 [18] and 3 [18] , NS).
CONCLUSIONS -Our randomized double-blind crossover trial has demonstrated that short-term treatment with 150 mg ASA daily does not have any clinical impact on urinary AER, GFR, and TER alb in type 1 diabetic patients with microalbuminuria receiving antihypertensive treatment. Consequently, primary and secondary prevention of cardiovascular events with low-dose ASA does not interfere with the classification of albuminuria or monitoring of antiproteinuric treatment in these patients.
Low-dose ASA (40-325 mg/day) has been shown to offer substantial primary (5,6) and secondary protection against macrovascular morbidity and mortality in diabetic patients at high risk for cardiovascular events (7) . Previous studies support the concept that the inactivation of the constitutive platelet cyclooxygenase-1 by ASA, and the consequent reduced formation of platelet thromboxane, largely account for the antithrombotic effects of ASA (17, 18) .
Elevated renal synthesis of vasodilating prostaglandins has been demonstrated in type 1 diabetic patients with microalbuminuria (9) , and inhibition with high-dose indometacin (150 mg/day), another inhibitor of cyclooxygenase-1, induced a reduction in renal prostaglandin synthesis, urinary AER, and alb , while GFR remained stable (9) . Furthermore, treatment with high-dose ASA (990 mg ASA ϩ 225 mg dipyridamole daily) reduced urinary AER in type 1 diabetic patients with diabetic nephropathy (10) . These effects occur shortly after start of treatment. On the contrary, our study showed that urinary AER, alb , and GFR remained unchanged during short-term treatment with low-dose (150 mg/day) ASA. The tubular protein reabsorption capacity is normal in type 1 diabetic patients with microalbuminuria (19) , suggesting that microalbuminuria is of glomerular origin. The transglomerular passage of albumin is determined by the size-and charge-selective properties of the glomerular capillary wall and the transglomerular hydraulic pressure (20) . We have no direct information on these variables; however, our data indirectly suggest that low-dose ASA does not affect the intrarenal synthesis of prostaglandins.
A possible pathophysiological link between elevated urinary AER and cardiovascular disease has been hypothesized by Deckert et al. (21) , who suggested that albuminuria reflects widespread vascular damage due to generalized vascular (endothelial) dysfunction (the Steno hypothesis). This concept has been supported by the finding of increased TER alb in type 1 diabetic patients with microalbuminuria (22) . The TER alb is determined by the permeability surface area product of the microvasculature and the transcapillary hydraulic pressure gradient (23) . The permeability is governed by the size-and charge-selective properties of the capillary barrier. Our study has confirmed that the TER alb is elevated in type 1 diabetic patients with microalbuminuria (22) . Since systemic BP remained unchanged during the present study, it seems reasonable to conclude that no major changes in size or charge selectivity were observed during low-dose ASA therapy.
In conclusion, treatment with low-dose ASA (150 mg once a day) does not have any clinical impact on urinary AER, GFR, or the TER alb in type 1 diabetic patients with microalbuminuria. Consequently, primary and secondary prevention of cardiovascular events with low-dose ASA does not interfere with the correct classification of albuminuria or monitoring of antiproteinuric treatment. 
